At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 530 enrolled
Drug / intervention
Favipiravir +2 moredrug
Likely dose
Favipiravir 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Favipiravir in Adult Patients With Uncomplicated Influenza
In Brief
A Phase 2 clinical trial evaluating Favipiravir and Placebo comparator for Influenza. Completed, enrolled 530 participants across 228 sites in 7 countries.
Detailed Summary
This is a Phase 2, randomized, double-blind, placebo-controlled multicenter study evaluating the efficacy and safety of two doses of favipiravir in adult patients with uncomplicated influenza.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesAustralia, Chile, New Zealand, Paraguay, Peru, South Africa, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
First PostedFeb 2010
Primary CompletionApr 2012
Study CompletionMay 2012
TodayJul 2026
First PostedFeb 15, 2010
Enrollment StartFeb 1, 2010
Primary CompletionApr 1, 2012
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 16.4 years ago
Interventions
Favipiravirdrug
1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days
Favipiravirdrug
High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
Placebo comparatordrug
Placebo BID x 1 day, and Placebo BID x 4 days